Setterwalls acts as legal advisor to InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”), whose shares are listed on Nasdaq First North Growth Market, in connection with a SEK 140 million directed issue to Swedish and international institutional investors, such as the Fourth Swedish National Pension Fund and Stiftelsen Industrifonden, on the basis of an accelerated book building procedure carried out by the Company’s financial advisors, Carnegie and Pareto.
A main part of the directed new issue was resolved by the board of directors based on their authorization from the annual general meeting, while the remaining shares were issued subject to the approval of an extraordinary general meeting on 9 October 2019.
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. The private placement is, inter alia, intended to finance planned preparations for a phase III program.